Pillar Biosciences Expands Access to Cutting-edge Cancer Testing
Pillar Biosciences, the leader in Decision Medicine™, is making significant strides in the area of cancer diagnostics. Recently, the company celebrated a landmark achievement with the announcement of nationwide Medicare coverage for its oncoReveal® CDx pan-cancer solid tumor in vitro diagnostic (IVD) kit. This decision by the Centers for Medicare & Medicaid Services (CMS) is set to revolutionize how genomic testing is utilized, enabling better outcomes for patients battling cancer.
Understanding oncoReveal® CDx Technology
The oncoReveal® CDx is an advanced next-generation sequencing (NGS) IVD kit. It utilizes the innovative SLIMamp (Stem-Loop Inhibition-Mediated amplification) technology developed by Pillar. This kit facilitates the detection of critical single nucleotide variants (SNVs), insertions, and deletions across 22 genes. Importantly, it employs DNA from formalin-fixed paraffin-embedded (FFPE) tumor specimens, making it a practical choice for oncologists handling previously diagnosed cancer patients with solid malignant neoplasms.
Applications in Oncology
oncoReveal® CDx provides an invaluable tool for pan-cancer tumor mutation profiling. This capability is crucial for qualified healthcare professionals who require precise information to guide treatment decisions. The kit has also received approval as a companion diagnostic. It specifically identifies patients who might benefit from therapies like EGFR TKI in non-small cell lung cancer (NSCLC) and is relevant in the assessment of KRAS mutations for treatments involving ERBITUX® and VECTIBIX® in colorectal cancer.
Impact of Medicare Coverage
This new coverage allows for increased accessibility to oncoReveal® CDx testing for over 66 million Medicare users in the United States. According to Brian Wright, the Chief Marketing Officer of Pillar Biosciences, this is a vital milestone that ensures affordable and rapid access to FDA-approved NGS testing. It facilitates local testing, promoting timely treatment decisions and overall better health outcomes.
Partnership with Illumina
Pillar Biosciences is proud to collaborate with Illumina in this endeavor. Traci Pawlowski, Vice President and Head of Clinical Solutions at Illumina, emphasized the importance of making genomic testing accessible and affordable to improve patient care. This partnership exemplifies how combining innovative technology with healthcare solutions can enhance the standard of cancer treatment and patient support.
The Future of Cancer Diagnostics
The oncoReveal® CDx is significant not just for its advanced technology but also for what it represents in the broader context of cancer diagnostics. As treatments continue to evolve, the need for precise and personalized therapy is paramount. Pillar Biosciences is at the forefront of this evolution, offering solutions that facilitate informed decisions for healthcare providers and patients alike.
Ongoing Development and Availability
Pillar Biosciences has developed over 20 NGS testing kits available in both IVD and RUO formats. These kits serve various cancer types and are at different stages of development, emphasizing the company’s commitment to innovative and accessible cancer diagnostics. With proactive measures like obtaining CMS coverage, Pillar aims to enhance the utility and efficiency of NGS testing around the world.
About Pillar Biosciences
Pillar Biosciences stands as a leader in Decision Medicine™, utilizing highly accurate and sensitive NGS testing technology. This approach generates data that is crucial for selecting precision therapies tailored for patients suffering from cancer. Integrating its proprietary technologies, such as SLIMamp® and PiVAT®, Pillar optimizes processes, reduces costs, and enhances access to effective NGS testing across the globe. The firm is dedicated to supporting healthcare professionals in making informed decisions to improve patient care.
Frequently Asked Questions
1. What is the oncoReveal® CDx kit?
The oncoReveal® CDx kit is a next-generation sequencing IVD kit that detects cancer-related genetic mutations.
2. Why is Medicare coverage significant for the oncoReveal® CDx kit?
Medicare coverage ensures that this advanced test is accessible and affordable for millions of patients, facilitating improved cancer care.
3. How does the oncoReveal® CDx technology work?
It uses proprietary amplification technology to analyze DNA from tumor tissues, identifying mutations across multiple genes.
4. What role does Illumina play in this partnership?
Illumina collaborates with Pillar Biosciences to enhance the accessibility and affordability of genomic testing for cancer patients.
5. What are the future plans for Pillar Biosciences?
Pillar aims to expand its portfolio of NGS testing kits and improve patient access to innovative cancer diagnostics.
